HOSPITAL COSTS AND HEALTHCARE UTILIZATION RESOURCES OF INVASIVE FUNGAL DISEASE IN CHINA: A RETROSPECTIVE REAL WORLD STUDY
Author(s)
Xiaochen Zhu, MSc, Xinyao Li, MSc, Sheng Han, Ph.D.;
International Research Center for Medicinal Administration, Peking University, Beijing, China
International Research Center for Medicinal Administration, Peking University, Beijing, China
OBJECTIVES: Invasive fungal diseases (IFD) are severe and systemic fungal infections that affect organs, blood, or mucous membrane. IFD imposes substantial burden on healthcare system but real-world evidence is limited. This study assessed hospital costs and healthcare resource utilization (HCRU) of Chinese IFD patients.
METHODS: This real-world study retrospectively identified adult patients diagnosed with proven, probable, or possible IFD, hospitalized between 2006 and 2021 in Tianjin, a major economic hub in northern China. Demographic, clinical, and cost data were extracted from Tianjin Healthcare and Medical Big Database, a regional electronic health record database covering more than 300 hospitals.Inpatient costs and HCRU were reported and quantile regressions were employed to explore impacting factors of inpatient costs across distribution.
RESULTS: 4,826 inpatients were included (mean age 59 years; 56.67% male;15.73% uninsured). Hematological diseases (35.76%), coronary heart disease (21.22%) and solid cancer (17.57%) were the top comorbidities. 86.05% were administered antifungals and 76.43% received monotherapy. Voriconazole (41.44%) and fluconazole (24.25%) were the most commonly-used. The average hospital length of stay per inpatient was 24.01 days. 6.96% were admitted to ICU. The mean total inpatient cost was 71,874.99 CNY per inpatient, principally attributable to medications (39,747.26 CNY), laboratory tests (9,525.69 CNY), and treatments (6,717.62 CNY). IFD inpatients with hematological diseases had the highest mean inpatient costs, almost 2.5 times compare to those without (116,614.3 vs. 46,965.28 CNY), followed by severe pneumonia(105,438.4 CNY) and respiratory failure (100,484.5 CNY). Quantile regressions showed that hematological diseases and respiratory failure were significantly associated with higher costs across the distribution, whereas chronic obstructive pulmonary disease was linked to lower costs at higher percentiles.
CONCLUSIONS: Chinese IFD inpatients particularly those with severe comorbidities incur substantial resource use and cost burden, highlighting the complexity in IFD treatment. Enhanced capacities to treat IFD in more cost-effective way by comorbidy might help reduce the economic burden.
METHODS: This real-world study retrospectively identified adult patients diagnosed with proven, probable, or possible IFD, hospitalized between 2006 and 2021 in Tianjin, a major economic hub in northern China. Demographic, clinical, and cost data were extracted from Tianjin Healthcare and Medical Big Database, a regional electronic health record database covering more than 300 hospitals.Inpatient costs and HCRU were reported and quantile regressions were employed to explore impacting factors of inpatient costs across distribution.
RESULTS: 4,826 inpatients were included (mean age 59 years; 56.67% male;15.73% uninsured). Hematological diseases (35.76%), coronary heart disease (21.22%) and solid cancer (17.57%) were the top comorbidities. 86.05% were administered antifungals and 76.43% received monotherapy. Voriconazole (41.44%) and fluconazole (24.25%) were the most commonly-used. The average hospital length of stay per inpatient was 24.01 days. 6.96% were admitted to ICU. The mean total inpatient cost was 71,874.99 CNY per inpatient, principally attributable to medications (39,747.26 CNY), laboratory tests (9,525.69 CNY), and treatments (6,717.62 CNY). IFD inpatients with hematological diseases had the highest mean inpatient costs, almost 2.5 times compare to those without (116,614.3 vs. 46,965.28 CNY), followed by severe pneumonia(105,438.4 CNY) and respiratory failure (100,484.5 CNY). Quantile regressions showed that hematological diseases and respiratory failure were significantly associated with higher costs across the distribution, whereas chronic obstructive pulmonary disease was linked to lower costs at higher percentiles.
CONCLUSIONS: Chinese IFD inpatients particularly those with severe comorbidities incur substantial resource use and cost burden, highlighting the complexity in IFD treatment. Enhanced capacities to treat IFD in more cost-effective way by comorbidy might help reduce the economic burden.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE125
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Infectious Disease (non-vaccine)